DK0971735T3 - Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom - Google Patents

Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom

Info

Publication number
DK0971735T3
DK0971735T3 DK98912149T DK98912149T DK0971735T3 DK 0971735 T3 DK0971735 T3 DK 0971735T3 DK 98912149 T DK98912149 T DK 98912149T DK 98912149 T DK98912149 T DK 98912149T DK 0971735 T3 DK0971735 T3 DK 0971735T3
Authority
DK
Denmark
Prior art keywords
compositions
treatment
methods
inflammatory bowel
bowel disease
Prior art date
Application number
DK98912149T
Other languages
Danish (da)
English (en)
Inventor
Thomas Julius Borody
Original Assignee
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Borody Thomas J filed Critical Borody Thomas J
Application granted granted Critical
Publication of DK0971735T3 publication Critical patent/DK0971735T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98912149T 1997-04-01 1998-04-01 Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom DK0971735T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease
PCT/AU1998/000222 WO1998043667A1 (en) 1997-04-01 1998-04-01 Methods and compositions for treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
DK0971735T3 true DK0971735T3 (da) 2008-07-07

Family

ID=25645389

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98912149T DK0971735T3 (da) 1997-04-01 1998-04-01 Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom

Country Status (16)

Country Link
US (1) US6277836B1 (enExample)
EP (1) EP0971735B1 (enExample)
JP (3) JP2001524951A (enExample)
AR (1) AR012304A1 (enExample)
AT (1) ATE389417T1 (enExample)
CA (1) CA2285923C (enExample)
CY (1) CY1109783T1 (enExample)
DE (1) DE69839261T2 (enExample)
DK (1) DK0971735T3 (enExample)
ES (1) ES2303351T3 (enExample)
IL (1) IL132145A (enExample)
NO (1) NO325947B1 (enExample)
NZ (1) NZ500696A (enExample)
PT (1) PT971735E (enExample)
SI (1) SI0971735T1 (enExample)
WO (1) WO1998043667A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
EP1150666B1 (en) * 1999-02-12 2009-10-28 Washington University Gm-csf for the treatment of crohn's disease
AR025976A1 (es) 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
EP1642885B1 (en) * 2000-08-29 2009-11-11 Biocon Limited Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
CA2508792C (en) 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
WO2004082586A2 (en) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
US7417037B2 (en) * 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
HUE029189T2 (en) 2004-02-06 2017-02-28 Pharmatel (R&D) Pty Ltd As Trustee For The Pharmatel (R & D) Trust The use of aminosalicylates in diarrhea prodominant irritable bowel syndrome
KR20130028807A (ko) * 2004-05-28 2013-03-19 샐릭스 파마슈티컬스 인코포레이티드 방사선 유발성 장염의 예방, 치료 및 개선 방법
CA2568914C (en) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
HUE028158T2 (en) 2004-07-07 2016-12-28 Biocon Ltd Synthesis of bound immunoregulatory compounds
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN102670626A (zh) * 2005-08-24 2012-09-19 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
US20090131343A1 (en) * 2007-11-15 2009-05-21 Ly Tam Phan Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
CA2714043C (en) * 2008-02-08 2016-11-08 Giaconda Limited Methods and compositions for treating inflammatory bowel disease
EP2280713A1 (en) * 2008-05-01 2011-02-09 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
US20110082120A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Substituted thioacetic acid salicylate derivatives and their uses
AU2010312309B2 (en) * 2009-10-26 2016-10-06 Thomas Julius Borody Novel enteric combination therapy
BR112012027520A2 (pt) 2010-04-26 2015-09-15 Salix Pharmaceuticals Ltd formulações e usos de derivados de ácido 2-hidroxi-5-fenilazobenzoico para o tratamento de indivíduos do sexo masculino
SG191145A1 (en) 2010-12-13 2013-07-31 Borody Thomas J Gastric and colonic formulations and methods for making and using them
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
SMT201900411T1 (it) 2012-06-19 2019-09-09 Debiopharm Int Sa Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
WO2014016671A2 (en) 2012-07-27 2014-01-30 Redhill Biopharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
EP3145510B8 (en) * 2014-05-22 2021-10-27 Kuenstner, John, Todd Treatment of diseases using combination of ultraviolet blood irradiation and antibiotics
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
FI3923914T3 (fi) 2019-02-14 2023-04-27 Debiopharm Int Sa Afabisiiniformulaatio, menetelmä sen valmistamiseksi
MA56184A (fr) 2019-06-14 2022-04-20 Debiopharm Int Sa Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm
CA3187031A1 (en) 2020-06-30 2022-01-06 Redhill Biopharma Ltd. Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
ES2303351T3 (es) 2008-08-01
WO1998043667A1 (en) 1998-10-08
ATE389417T1 (de) 2008-04-15
US6277836B1 (en) 2001-08-21
IL132145A0 (en) 2001-03-19
CA2285923C (en) 2013-03-12
NZ500696A (en) 2002-05-31
NO325947B1 (no) 2008-08-25
SI0971735T1 (sl) 2008-08-31
JP2001524951A (ja) 2001-12-04
EP0971735B1 (en) 2008-03-19
CA2285923A1 (en) 1998-10-08
JP2012126736A (ja) 2012-07-05
CY1109783T1 (el) 2013-09-04
NO994778D0 (no) 1999-09-30
AR012304A1 (es) 2000-10-18
DE69839261D1 (de) 2008-04-30
DE69839261T2 (de) 2009-03-26
EP0971735A4 (en) 2004-02-25
IL132145A (en) 2005-11-20
PT971735E (pt) 2008-06-02
EP0971735A1 (en) 2000-01-19
NO994778L (no) 1999-11-30
JP2008024713A (ja) 2008-02-07

Similar Documents

Publication Publication Date Title
DK1003479T3 (da) Fremgangsmåde og sammensætninger til behandling af allergiske senfasereaktioner og inflammatoriske sygdomme
NO994778L (no) Fremgangsmåter og preparater for behandling av inflammatorisk tarmsyndrom
DK1148875T3 (da) Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer
DK1109453T3 (da) Sammensætninger og fremgangsmåder til behandling af mitokondrielle sygdomme
NO20003096D0 (no) Sammensetninger og fremgangsmÕter for behandling av ADD
DK1352895T3 (da) Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme
DK0785770T3 (da) Sammensætninger til bekæmpelse af hæmorroider og fremgangsmåde til anvendelse deraf
DK0966447T3 (da) Anvendelige små molekyler til behandling af betændelsessygdomme
NO20012916D0 (no) Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser
NO973046D0 (no) Elastiske sementsammensetninger og fremgangsmåte
NO973048D0 (no) Elastiske sementsammensetninger og fremgangsmåter
DK0990391T3 (da) Phytosterolholdig fedtsammensætning
DK1123313T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
NO20000011D0 (no) Skumdempersammensetninger og fremgangsmåter
DK1749534T3 (da) Anvendelse af parasitære biologiske midler til forebyggelse og kontrol af inflammatorisk tarmsygdom
NO20002849D0 (no) Sammensetninger og metoder for Õ indusere genekspersjon
DE69730092D1 (de) Photovernetzbare Siliconzusammensetzungen
DK0980246T3 (da) Behandling af tarmforstoppelse
DK0772443T3 (da) Prednisolonmetasulfobenzoat-præparat til behandling af inflammatorisk tarmsygdom
DE60010959D1 (de) Resistzusammensetzungen und Bildaufzeichnungsverfahren
KR970000230A (ko) 염증성 장 질환을 치료하기 위한 캅파-아편제 작용물질
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
NO996090D0 (no) Forbedret foskefor og fremgangsmåte for anvendelse av dette
DK0790998T3 (da) Azo-derivater af 5-aminosalicylsyre til behandling af inflammatorisk tarmsygdom
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom